Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 8

Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

February 4, 2025

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM

EP. 6: Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

EP. 7: Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

Now Viewing

EP. 8: Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

Video content above is prompted by the following:

Dr Rodriguez to Dr Efebera: Please comment on the latest efficacy data from CARTITUDE-4, evaluating cilta-cel in patients with R/R MM.
Dr Rodriguez to Dr Efebera: CARTITUDE-4, MRD negativity
Dr Rodriguez to faculty: How do real-world and/or patient-reported outcomes inform your decision of CAR T for early-stage R/R MM?
Dr Rodriguez to Dr Nadeem: CARTITUDE-4, patient-reported outcomes Dr Rodriguez to Dr Neparidze: Comparison, standard-of-care ide-cel and cilta-cel in R/R MM: